Dermatology News and Research

Latest Dermatology News and Research

Ceragenix Pharmaceuticals updates license agreement covering antimicrobial technology use

Ceragenix Pharmaceuticals, Inc. ("Ceragenix" or the “Company”), a medical device company focused on infectious disease and dermatology, today provided an update to a previously announced exclusive evaluation and option to license agreement (the "Agreement”) with a global, multi-billion dollar healthcare company covering the use of the Company's CeraShield antimicrobial technology for a specific medical device associated with a high incidence of hospital acquired infections.

1 Sep 2009

NASDAQ Stock Market issues noncompliance letter to Encorium Group

Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on August 25, 2009, it received a letter from The NASDAQ Stock Market notifying the Company that, based on its Form 10-Q for the period ended June 30, 2009, NASDAQ has determined that the Company's stockholders' equity does not comply with the minimum $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market as required by NASDAQ Marketplace Rule 5550(b)(1).

1 Sep 2009

Study provides insights into genes that help maintain youthfulness of the skin

In the new print issue of Nature Genetics, scientists in Singapore and Germany report that mutations in the PYCR1 gene cause the rare genetic condition that results in premature skin aging and that is known as "wrinkly skin syndrome."

1 Sep 2009

Elorac offers Zithranol-RR for treating plaque psoriasis

Now patients with mild to moderate plaque psoriasis have a new topical treatment option available by prescription. Zithranol™-RR (anthralin rapid release microcrystalline encapsulated cream, 1.2%), is an innovative topical therapy for plaque psoriasis according to Elorac, Inc., a privately held emerging dermatology company. Zithranol™-RR provides an advanced delivery system for anthralin achieving long remission times with no long-term side effects in a steroid-free, silky cream.

28 Aug 2009

Novel methodology developed to extract microRNAs from cancer tissues

Researchers led by Dr. Soheil Dadras at the Stanford University Medical Center have developed a novel methodology to extract microRNAs from cancer tissues. The related report by Ma et al, "Profiling and discovery of novel miRNAs from formalin-fixed paraffin-embedded melanoma and nodal specimens," appears in the September 2009 issue of the Journal of Molecular Diagnostics.

28 Aug 2009

HLA-Cw*0602 gene variation detected as a high risk for psoriasis

A specific genetic region that has been increasingly identified as the strongest genetic link to psoriasis has an even more significant role in the chronic skin disease than has been suspected, University of Utah medical researchers show in a new study.

27 Aug 2009

Research finds that people with psoriasis are less likely to react to looks of disgust by others

People with psoriasis - an often distressing dermatological condition that causes lesions and red scaly patches on the skin - are less likely to react to looks of disgust by others than people without the condition, new research has found.

From The University of Manchester 27 Aug 2009

New online educational forum for medical professionals from HMP Communications

HMP Communications, the authoritative source for education services targeting healthcare professionals for over two decades, announced it has added a new online educational forum at www.CardiovascularLIVE.com. The site offers video instruction and discussion forums for medical professionals.

26 Aug 2009

Awareness campaign on sun protection by Portland dermatologists at the LPGA Safeway Classic

In a region known more for its rainfall than sunshine, a team of Portland dermatologists representing the Women's Dermatologic Society (WDS) will return for the third time in six years to the LPGA Safeway Classic to promote sun safety for all seasons and skin types. This picturesque yet often cloudy venue has proven to draw golf lovers who need greater awareness about skin protection, as shown by the previous screenings' 37% skin cancer discovery rate.

25 Aug 2009

Encorium releases second-quarter 2009 results

Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced its financial results for the second quarter ended June 30, 2009.

24 Aug 2009

P&G's global pharmaceuticals business sold to Warner Chilcott for $3.1 billion

The Procter & Gamble Company and Warner Chilcott plc today announced an agreement for the sale of P&G's global pharmaceuticals business to Warner Chilcott for an up-front cash payment of $3.1 billion.

24 Aug 2009

Retigabine's Phase IIa clinical trial preliminary results announced

Valeant Pharmaceuticals International today announced preliminary results from its Phase IIa proof-of-concept clinical trial of retigabine for the treatment of pain associated with postherpetic neuralgia (PHN), a painful and common complication of shingles.

24 Aug 2009

Foamix's novel foam technology awarded US patent

Foamix Ltd., a leading developer of topical foams for dermatology and gynecology, announced today that it has been awarded US Patent #7575739 pertaining to its foam technology. The patent covers unique foam compositions, suitable for the treatment of heat and chemical burns, wounds, bacterial, fungal and viral infections.

24 Aug 2009

Clinic Service Corporation becomes the exclusive medical billing services provider to Colorado West Dermatology

Clinic Service Corporation (CSC), the leader in Colorado Practice Management Solutions, announced today the firm has secured an agreement to be the exclusive provider of medical billing services to Colorado West Dermatology.

21 Aug 2009

Health Canada approves Anika Therapeutics' MONOVISC drug

Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.

21 Aug 2009

Peplin completes four-week enrolment phase for REGION-Ib trial

Peplin, Inc. (ASX:PLI) today announced completion of enrolment in its second Phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on non-head treatment areas, which include the trunk and extremities. This completes enrolment in the final of four pivotal trials planned for the submission of the New Drug Application (NDA) for AK.

20 Aug 2009

Researcher of LA BioMed elected to distinguished fellow status of SVS

Carlos E. Donayre, MD, a researcher at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), has been elected to distinguished fellow status of the Society for Vascular Surgery- (SVS).

20 Aug 2009

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.

19 Aug 2009

New tumour theory could change cancer treatment

University of Sydney researcher Dr Guy Lyons has come up with a new theory of cancer tumours that could change the way we treat cancer and conduct research into its causes.

13 Aug 2009

Transcript: President Obama Town Hall meeting in New Hampshire

President Barack Obama continued his press for public support of health reform initiatives at what the White House called a "Health Insurance Reform Town Hall" meeting at Portsmouth High School in Portsmouth, New Hampshire.

12 Aug 2009